Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Gosho M, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S.
Fujisawa Y, et al. Among authors: furudate s.
J Dermatol Sci. 2017 Nov;88(2):225-231. doi: 10.1016/j.jdermsci.2017.07.007. Epub 2017 Jul 16.
J Dermatol Sci. 2017.
PMID: 28736218